



IFW

Atty. Dkt. No. 074129-0521

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Kouhei TOYOOKA, et al.

Title: ISOINDOLINE DERIVATIVES

Appl. No.: 10/534,414

International Filing Date: 5/11/2005

371(c) Date: 5/11/2005

Examiner: Unassigned

Art Unit: 1615

Confirmation Number:

7101

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

RELEVANCE OF EACH DOCUMENT

Documents B5-B14 are cited in the present specification. The relevance of the foreign-language documents is described in the present specification. An English translation of the foreign-language documents is not readily available. However, the absence of such translation does not relieve the PTO from its duty to consider the submitted foreign language documents (37 CFR §1.98 and MPEP §609). English language abstracts are attached.

Document B1 is the U.S. counterpart of Document B5.

Documents B2 and B3 are the U.S. counterparts to Document B6.

Document B4 is the U.S. counterpart to Document B7.

Although Applicants believe that no fee is required for this Request, the Commissioner is hereby authorized to charge any additional fees which may be required for this Request to Deposit Account No. 19-0741.

Respectfully submitted,

Date Feb. 23, 2007

By 

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5571
Facsimile: (202) 672-5399

for Harold C. Wegner Matthew Mulkeen
Attorney for Applicant
Registration No. 25,258 Reg. No 44,250

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT FEB 23 2007 Date Submitted: FEB 23 2007 (use as many sheets as necessary) Sheet 1 of 2			Complete if Known	
			Application Number	10/534,414
			Filing Date	5/11/2005
			First Named Inventor	Kouhei TOYOOKA
			Art Unit	Unassigned
			Examiner Name	Unassigned
			Attorney Docket Number	074129-0521

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	B1	3,818,011	06-18-1974	Challier et al.	
	B2	4,056,635	11-01-1977	Glen et al.	
	B3	4,452,817	06-05-1984	Glen et al.	
	B4	4,590,189	05-20-1986	Hiraga et al.	

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Application Document	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
	B5	JP 47-12322	06-22-1972		Abst.
	B6	JP 50-154410	12-12-1975		Abst.
	B7	JP 58-189163	11-04-1983		Abst.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	B8	NEWMAN et al., "The Behavior of 3,6-Dimethylphthalic Anhydride in Friedel-Crafts and Grignard Condensations." <i>Journal of American Chemistry Society</i> , May 1944, pp. 733-735, Vol. 66.			
	B9	CAMENZIND et al., "Synthesis of 2,3,9,10,16,17,23,24-Octaethylphthalocyanine." <i>Journal of Heterocyclic Chemistry</i> , March - April 1985, pp. 575-576, Vol. 22.			
	B10	TAUB et al., "Total Synthesis of the Macrolide Zearalenone." <i>Tetrahedron</i> , September 12, 1967, pp. 2443-2461, Vol. 24.			
	B11	HUNG et al., "Central Nervous System Active compound. VI Reissert Compounds as Precursors of 1-(3-Phthalidyl)isoquinolines." <i>Journal of Chemistry</i> , 1981, Vol. 34.			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/534,414
Date Submitted: <i>(use as many sheets as necessary)</i>				Filing Date	5/11/2005
				First Named Inventor	Kouhei TOYOOKA
				Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	074129-0521
Sheet	2	of	2		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
	B12	KEANA et al., "Synthesis and Properties of Some Nitroxide α -Carboxylate salts." <i>Journal of Organic Chemistry</i> , 1989, pp. 2417-2420, Vol. 54.		
	B13	TAPIA et al., "2-3-Dihydro-2-oxo-1H-benzimidazole-1-carboxamides with Selective Affinity for the 5-HT ₄ Receptor: Synthesis and Structure-Affinity and Structure-Activity Relationships of a New Series of Partial Agonist and Antagonist Derivatives." <i>Journal of Medical Chemistry</i> , 1999, pp. 2870-2880, Vol. 42.		
	B14	SCHUDA et al., "The Synthesis of 4-Oxo-2-pentenoic Esters by Wittig Reaction Using α -Oxoesters." <i>Synthesis</i> , December 1987, pp. 1055-1057.		
	B15	ABELL et al., "Aspects of the Mechanism of the Wittig Reaction Between Cyclic Anhydrides and Stabilized Phosphoranes." <i>Journal of Chemistry</i> , 1982, pp. 2077-2087, Vol. 35		
	B16	MALI et al., "A Novel Synthesis of N-Substituted-3-carboethoxymethylphthalimidines." <i>Synthesis Communications</i> , September 1986, pp. 755-757.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.